MarketCap
Facebook
X
Telegram
Sage Therapeutics DSO Ratio | SAGE
Annual DSO Ratio Sage Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 408 | 204 | 324 | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 408 | 204 | 312 |
Quarterly DSO Ratio Sage Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.9 | 64.4 | - | 95.4 | 108 | 540 | - | 378 | - | 189 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.32 | 9.32 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 540 | 9.32 | 159 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
258 | $ 294.72 | 0.32 % | $ 521 B |  USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Achieve Life Sciences
ACHV
|
36.8 | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
134 | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
83.9 | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.33 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Cytokinetics, Incorporated
CYTK
|
71.3 | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.3 | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
81.2 | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
22.6 | - | -33.86 % | $ 61.2 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
66.2 | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
62 | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
729 | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
119 | - | - | $ 121 M | USA |
 |
C4 Therapeutics
CCCC
|
27.9 | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
80.5 | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
211 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
48.3 | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
MediciNova
MNOV
|
365 | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
114 | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
63.2 | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
50.9 | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
11.6 | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Nektar Therapeutics
NKTR
|
2.23 | $ 38.41 | 1.67 % | $ 648 M | USA |
 |
CorMedix
CRMD
|
130 | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.3 K | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
65.6 | $ 1.66 | -2.64 % | $ 1.12 B | Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
158 | - | -23.04 % | $ 26.6 M | USA |
 |
Verona Pharma plc
VRNA
|
136 | - | - | $ 69.7 B | Britain |